UC Davis

Anesthesiology and Pain Medicine

Title

EVALUATION OF REINTUBATION RATES FOLLOWING INTRODUCTION OF NEW REVERSAL AGENT

Permalink

https://escholarship.org/uc/item/1nk763gm

Authors

Soudan, Colton Nguyen, Kevin Fleming, Neal

Publication Date

2020

Data Availability


The data associated with this publication are not available for this reason: N/A

EVALUATION OF REINTUBATION RATES FOLLOWING INTRODUCTION OF NEW REVERSAL AGENT

Presenter: Colton Soudan


Background

- Postoperative residual neuromuscular blockade is associated with post-op complications
- Current blockade reversal agents are Sugammadex and Neostigmine
- Sugammadex may decrease postoperative residual neuromuscular blockade
- Sugammadex was introduced to UC Davis Academic Center on 3/11/16



Methods

- Used EMR and chart review to find patients requiring post-operative tracheal reintubation
- Observed previously associated patient characteristics, as well as new factors, as shown in table 1 and 2




Results

- 52 patients required tracheal reintubation; 37
 before and 15 after Sugammadex
- Significant decrease in the frequency of tracheal reintubations comparing the post-Sugammadex introduction to the pre-Sugammadex introduction group
- Significant decrease in frequency of reintubation comparing Sugammadex to Neostigmine in Post-Sugammadex introduction group

Following the introduction of Sugammadex, tracheal reintubation frequency decreased at UC Davis Medical Center

QR Code goes here



Take a picture to download the abstract

| ble 1: Pre and Post-Sugammadex Introduction Breakdown | Pre-Sugammadex | Post Sugammadex |
|---|----------------|-----------------|
| Dates | 7/2/14-3/10/16 | 3/11/16-3/14/18 |
| Total Non-depolarizing NMBA Use | 23,533 | 30,742 |
| Total Patients Requiring Tracheal Reintubation | 37 | 15 |
| Frequency of Tracheal Reintubations | 0.16%* | 0.05%* |
| Reintubations per Month | 1.8 | 0.6 |
| Patient Characteristics for Reintubations | | |
| Average Age | 56.9 | 51.9 |
| Age Range | 3 to 83 | 3 to 83 |
| Age SD | 18.84 | 22.13 |
| Gender | 21F; 16M | 7F; 8M |
| Average BMI | 27.81 | 28.51 |
| Weight (kg) | 73.94 | 77.17 |
| Number of patients with HF | 6 | 5 |
| Number of Patients with COPD | 9 | 6 |
| Number of Patients with CKD | 5 | 6 |
| Number of patients with Intra-abdominal Surgery | 18 | 5 |
| ASA Classification 1 / 2 / 3 / 4 | 0/1/17/19 | 1/0/12/2 |
| Time of Surgery: 0-2 / 2-4 / 4+ Hours | 18 / 12 / 7 | 8/4/3 |
| Average Neuromuscular Blockade Agent Rocuronium Equivalent mg/kg | 1.2 | 1.2 |
| Number of Patients reversed with Neostigmine | 34 | 6 |
| Number of Patients reversed with Sugammadex | 0 | 6 |
| Number of Patients not given Reversal Agent | 3 | 3 |
| Average Reversal Agent Neostigmine mg/kg | 0.06 | 0.05 |
| Average Reversal Agent Sugammadex mg/kg | | 2.9 |
| Average time from Reversal Agent to Reintubation | 1:12 | 1:21 |
| Average time from last NMBA to RA | 1:16 | 1:22 |
| imber of Patients that desaturated <90% following initial tracheal intubation | 5 | 5 |
| *= P-value <.01 when compared | | |

Discussion

- Further research can explore how different patient and surgical characteristics can impact the frequency of tracheal reintubations
- Further research can examine patient population not receiving neuromuscular blockade reversal agent
- Further research could look at 30 day outcomes following tracheal reintubation

| Table 2: Post-Sugammadex Introduction Breakdown | Neostigmine | Sugammadex |
|--|-----------------|-----------------|
| Dates | 3/11/16-3/14/18 | 3/11/16-3/14/18 |
| Total Patients Receiving RA Post-Sugammadex Introduction | 4,455 | 19,379 |
| Total Patients Requiring Tracheal Reintubation | 6 | 6 |
| Reintubations per use of RA Post-Sugammadex Introduction | 0.13%* | 0.03%* |
| Patient Characteristics for Reintubations | | |
| Average Age | 62.7 | 41.3 |
| Age Range | 44 to 74 | 3 to 83 |
| Age SD | 14.14 | 29.76 |
| Gender | 4F; 2M | 2F; 4M |
| Average BMI | 31.08 | 27.13 |
| Weight (kg) | 85.82 | 61.97 |
| Number of Patients with HF | 1 | 1 |
| Number of Patients with COPD | 2 | 2 |
| Number of Patients with CKD | 5 | 1 |
| Number of patients with Intra-abdominal Surgery | 4 | 1 |
| ASA Classification 1 / 2 / 3 / 4 | 0/0/6/0 | 1/0/3/2 |
| Time of Surgery: 0-2 / 2-4 / 4+ Hours | 3/1/2 | 4/2/0 |
| Average Neuromuscular Blockade Agent Rocuronium Equivalent mg/kg | 1.4 | 1.2 |
| Number of Patients reversed with Neostigmine | 6 | 0 |
| Number of Patients reversed with Sugammadex | 0 | 6 |
| Average Reversal Agent mg/kg | 0.05 | 2.9 |
| Average time from Reversal Agent to Reintubation | 0:55 | 1:48 |
| Average time from last NMBA to RA | 1:26 | 1:18 |
| Number of Patients that desaturated <90% following initial tracheal intubation | 2 | 2 |
| *=P-value <.00001 when compared | | |
| | | |

References

- 1. Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev. 2017;8
- 2. Brueckmann, Britta, et al. "Development and Validation of a Score for Prediction of Postoperative Respiratory Complications." *Anesthesiology*, vol. 118, no. 6, 2013, pp. 1276–1285.
- Lukannek, C., et al. "The Development and Validation of the Score for the Prediction of Postoperative Respiratory Complications (SPORC-2) to Predict the Requirement for Early Postoperative Tracheal Re-Intubation: a Hospital Registry Study." *Anaesthesia*, vol. 74, no. 9, 2019, pp. 1165–1174

Colton Soudan, B.S., University of California, Davis Kevin Nguyen, B.S., University of California, Davis Neal Fleming, M.D., Ph.D., Department of Anesthesiology and Pain Medicine, University of California, Davis

